Samumed, LLC

Chugai Seiyaku Kabushiki Kaisha

Senomyx, Inc.

Biosplice Therapeutics, Inc.

Allylix, Inc.

Chevron U.s.a. Inc.

Massachusetts Institute of Technology

The University of Texas System

Rempex Pharmaceuticals, Inc.

Firmenich Incorporated

Other

Illinois Tool Works Inc.

David Mark Wallace

John Hood

Sunil Kumar Kc

Jianguo Cao

Chandramouli Chiruta

Charlene F Barroga

Thomas Arrhenius

Mi Chen

Jie Fei Cheng

Catherine Tachdjian

Sovouthy Tith

Venkataiah Bollu

Xiaodong Li

Luis A Dellamary

Mark Zoller

Guy Servant

Vincent Darmohusodo

Qing Chen

Andrew P Patron

Sunil Kumar K C

Gary David Lopaschuk

Xiao-Qing Tang

Jason Roland Dyck

Farid Bakir

Sara L Adamski-Werner

Marketa Rinnova

Amy Xing

Ming Qi

Daniel Harry Rogers

Stephen Terrence Hobson

Yusuf Yazici

Christopher Swearingen

Klaus Gubernator

Stephen Joseph Miller

Yoshiaki Watanabe

William John Koros

Yoshiyuki Ono

Joseph Timothy Marakovits

Bryan N Julien

Hirotaka Kashiwagi

John D Wind

Yujin Huang

Alex Michael Nadzan

Claudia Staudt-Bickel

Brian Walter Eastman

Chi Ching Mak

Lin Zhang

Richard Penuliar

Steven Ausnit

Tomasz W Glinka

Gopi Kumar Mittapalli

Masahiro Nishimoto

Keith A Bostian

Brian Joseph Hofilena

Marketa Lebl-Rinnova

Richard Julius Penuliar

Steve Joel Brown

Charles Stanford Harmon

Robert Hogan

Kenny Mccracken

Steven Olechowski

Gary D Lopaschuk

Jason R Dyck

Bin Liu

Eric Paul Plourde

Gavin C Hirst

William P Liteplo

David J Anzini

Mark E Wilson

Olga Rodny

Rusty Koenigkramer

Robert Higuchi

Olga Lomovskaya

William Fienup

De Q Vu

Rossy Serafimov

Kevin Owen

Clifton R Howell

Masayuki Haramura

Jie Fei Chang

David Anzini

William J Koros

Chun Chow

Barry Kudrowitz

Eric Plourde

Clifton Howell

C Staudt-Bickel

Charlene Barroga

Claudia Physikalisch-Chemisches Institut Staudt-Bickel

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof

The present disclosure provides &#x3b3;-diketones or analogs thereof, that activate Wnt/&#x3b2;-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

&#x3b3;-diketones as Wnt/&#x3b2;-catenin signaling pathway activators

Indazole compounds for treating various diseases and pathologies are provided. More particularly, the use of an indazole compound or analogs thereof, in the treatment of inflammatory diseases or disorders is provided.

2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

Treatment of osteoarthritis

The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the 'umami' taste of monosodium glutamate) or sweet taste modifiers, savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

Gamma-diketones as wnt/&#x3b2;-catenin signaling pathway activators

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

5-substituted indazole-3-carboxamides and preparation and use thereof

The present disclosure relates to indazole compounds having the following structure: or a pharmaceutically acceptable salt thereof, for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof

The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the 'umami' taste of monosodium glutamate) or sweet taste modifiers,&#x2014;savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof. 

3-(3H-imidazo[4,5-B]pyridin-2-yl)-1 H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof

Growing community of inventors

San Diego, CA, United States of America

David Mark Wallace